Crescent Biopharma, Inc. CBIO
13.70 USD +0.64 (+4.94%)
Nov 4, 2026, 3:34 PM EST
13.17 Day range 14.01
8.72 52-week range 27.41
- YTD
- +15.55%
- 1 year
- +10.17%
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 1
- 2 months ago 1
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.05 | -0.05 – -0.05 | 1.64 | -103.0% | 0 | 0.0% | 1 |
| Next quarter | -0.04 | -0.04 – -0.04 | -0.16 | +75.0% | 0 | 0.0% | 1 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | -0.03 | -0.03 – -0.03 | 0.00 | 0.0% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2021 | Raymond James | Downgrade | Outperform | Market Perform |
| Aug 5, 2021 | Raymond James | Maintained | — | Outperform |
| Apr 28, 2021 | Raymond James | Maintained | — | Outperform |
| Feb 9, 2021 | Piper Sandler | Initiated | — | Overweight |
| Feb 3, 2021 | Raymond James | Maintained | — | Outperform |
| Jan 3, 2019 | Oppenheimer | Initiated | — | Outperform |
| Jun 20, 2018 | B. Riley Securities | Downgrade | Buy | Neutral |
| Feb 11, 2018 | B. Riley Securities | Maintained | Buy | Buy |
| Feb 8, 2018 | Chardan Capital | Maintained | Buy | Buy |
| Dec 7, 2017 | B. Riley Securities | Initiated | — | Buy |
| Jun 11, 2017 | Chardan Capital | Initiated | — | Buy |
| Jun 5, 2017 | Ladenburg Thalmann | Initiated | — | Buy |
| Jun 29, 2016 | Rodman & Renshaw | Initiated | — | Buy |